Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer

Abstract Differentiated thyroid cancers (DTC) account for up to 85% of thyroid cancers and generally display an excellent prognosis. However, in a minority of cases, DTC progress toward less differentiated phenotypes leading to distant metastases and even disease-related deaths. Circulating biomarke...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	L. Giovanella, M. Imperiali, P. Trimboli
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6bc8fb423e2d43cabadae757b7927bbe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6bc8fb423e2d43cabadae757b7927bbe
record_format	dspace
spelling	oai:doaj.org-article:6bc8fb423e2d43cabadae757b7927bbe2021-12-02T16:08:00ZRole of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer10.1038/s41598-017-07915-02045-2322https://doaj.org/article/6bc8fb423e2d43cabadae757b7927bbe2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07915-0https://doaj.org/toc/2045-2322Abstract Differentiated thyroid cancers (DTC) account for up to 85% of thyroid cancers and generally display an excellent prognosis. However, in a minority of cases, DTC progress toward less differentiated phenotypes leading to distant metastases and even disease-related deaths. Circulating biomarkers are warranted to complement the gold standard DTC marker thyroglobulin (Tg) in identifying and monitoring such cases. We measured serum Tg and Cyfra 21.1 6 to 12 months after primary treatment in 473 DTC patients. A complete response of Tg was related to an excellent outcome in all cases. Among patients with incomplete Tg response Cyfra 21.1 levels <2.07 ng/mL were associated to favorable outcome while higher levels greatly increased the risk of disease related recurrences and deaths. Both markers retained independent prognostic values in multivariate analysis. In conclusion, Cyfra 21.1 is a tool available to independently predict survival of DTC patients not achieving excellent response after primary treatment.L. GiovanellaM. ImperialiP. TrimboliNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q L. Giovanella M. Imperiali P. Trimboli Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
description	Abstract Differentiated thyroid cancers (DTC) account for up to 85% of thyroid cancers and generally display an excellent prognosis. However, in a minority of cases, DTC progress toward less differentiated phenotypes leading to distant metastases and even disease-related deaths. Circulating biomarkers are warranted to complement the gold standard DTC marker thyroglobulin (Tg) in identifying and monitoring such cases. We measured serum Tg and Cyfra 21.1 6 to 12 months after primary treatment in 473 DTC patients. A complete response of Tg was related to an excellent outcome in all cases. Among patients with incomplete Tg response Cyfra 21.1 levels <2.07 ng/mL were associated to favorable outcome while higher levels greatly increased the risk of disease related recurrences and deaths. Both markers retained independent prognostic values in multivariate analysis. In conclusion, Cyfra 21.1 is a tool available to independently predict survival of DTC patients not achieving excellent response after primary treatment.
format	article
author	L. Giovanella M. Imperiali P. Trimboli
author_facet	L. Giovanella M. Imperiali P. Trimboli
author_sort	L. Giovanella
title	Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
title_short	Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
title_full	Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
title_fullStr	Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
title_full_unstemmed	Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
title_sort	role of serum cytokeratin 19 fragment (cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/6bc8fb423e2d43cabadae757b7927bbe
work_keys_str_mv	AT lgiovanella roleofserumcytokeratin19fragmentcyfra211asaprognosticbiomarkerinpatientswithdifferentiatedthyroidcancer AT mimperiali roleofserumcytokeratin19fragmentcyfra211asaprognosticbiomarkerinpatientswithdifferentiatedthyroidcancer AT ptrimboli roleofserumcytokeratin19fragmentcyfra211asaprognosticbiomarkerinpatientswithdifferentiatedthyroidcancer
_version_	1718384662078816256

Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer

Ejemplares similares